Mushroom Blend Cut Anxiety Scores and Boosted Sleep in a Double‐Blind Trial

When the first ten volunteers opened their sealed envelopes, the lab smelled of earth and pine. Those participants—office workers and graduate students who described “moderate” stress and occasional sleeplessness—completed baseline questionnaires on mood, fatigue and sleep quality. Six weeks later they returned, some rubbing sleepy eyes, others beaming, to repeat the same tests. The numbers that emerged sparked a fresh conversation about whether a handful of fungi can truly act as “adaptogens”—agents that help the body adapt to stress.

A Mushroom Blend Steps Into the Clinical Arena

Medicinal mushrooms have been staples of East Asian herbal medicine for centuries, touted for immune support, longevity and a host of other effects. In the West they appear as “functional foods” marketed as natural alternatives to pharmaceutical anxiolytics or sleep aids. The study’s authors note, however, that “scientific evidence from human studies remains limited.”

To address that gap, researchers designed a randomized, double‑blind, placebo‑controlled trial—the gold standard for testing efficacy. Fifty adult volunteers (age range not specified) were randomly assigned to receive either Restake, a proprietary blend of several adaptogenic mushroom species, or an indistinguishable placebo. The trial lasted 12 weeks, with assessments at baseline, week 6 and week 12.

Participants completed a suite of validated instruments:

• Pittsburgh Sleep Quality Index (PSQI) – global measure of sleep disturbances.
• Visual Analog Scale for Fatigue (VAS‑F) and Multidimensional Fatigue Inventory (MFI) – capture subjective and domain‑specific fatigue.
• State‑Trait Anxiety Inventory (STAI‑S) and Hamilton Anxiety Scale (HAM‑A) – assess anxiety.
• Perceived Stress Scale (PSS), Beck Depression Inventory (BDI) – assess stress and depressive symptoms.

In parallel, blood draws quantified serum cortisol, norepinephrine (NE), melatonin, adrenocorticotropic hormone (ACTH) and C‑reactive protein (CRP) using ELISA kits.

The investigators kept the study double‑blind: neither participants nor the staff who administered the questionnaires knew who received the mushroom blend. The placebo matched Restake in taste, texture and appearance, minimizing expectancy effects.

Numbers That Speak: Anxiety, Mood, and Fatigue

When the data were unblinded, the statistical contrasts painted a consistent picture of benefit for the Restake group.

• Anxiety: The State‑Trait Anxiety Inventory showed a greater reduction in the mushroom arm at week 6 (p = 0.025) and an even stronger difference at week 12 (p = 0.011). The clinician‑rated Hamilton Anxiety Scale mirrored this pattern, with p = 0.002 at both checkpoints.
• Depression: Beck Depression Inventory scores fell significantly in the Restake cohort, with a sharp drop at week 6 (p < 0.001) and a maintained improvement at week 12 (p = 0.008).
• Fatigue: Three domains of the Multidimensional Fatigue Inventory improved. General fatigue decreased (p = 0.043), physical fatigue (p = 0.027) and mental fatigue (p = 0.043). The visual analog scale corroborated these trends, though exact p‑values were not reported for VAS‑F.
• Sleep: The PSQI, where higher scores indicate poorer sleep, fell in the mushroom arm at week 6 (p = 0.005) and fell further by week 12 (p < 0.001). Participants reported fewer awakenings and felt more refreshed in the morning.

These p‑values indicate that the observed differences are unlikely to be due to chance alone, assuming the standard alpha of 0.05. The abstract does not disclose effect sizes (e.g., mean differences or Cohen’s d), leaving the magnitude of improvement open to interpretation.

Hormones in the Mix: A Physiological Footprint

Beyond self‑report, the study measured five biomarkers that sit at the crossroads of stress and sleep regulation. Four of them showed statistically significant shifts, while melatonin trended upward without reaching conventional significance.

• Cortisol and ACTH: Both fell dramatically in the Restake group (p < 0.001). Because cortisol is the end‑product of the hypothalamic‑pituitary‑adrenal (HPA) axis, a reduction suggests a dampened stress response.
• C‑reactive protein (CRP): A modest but significant drop (p = 0.042) hints at reduced systemic inflammation, a factor linked to both mood disorders and sleep disruption.
• Norepinephrine: Levels decreased (p = 0.033), potentially reflecting lower sympathetic arousal, which aligns with reduced anxiety scores.
• Melatonin: While not reaching statistical significance, the authors noted an “increased morning melatonin trend after 12 weeks,” suggesting a possible shift toward a healthier circadian rhythm.

These biomarker shifts provide a plausible mechanistic bridge between the mushroom blend and the observed psychological benefits. The mushrooms in Restake contain beta‑glucans, triterpenoids and other phytochemicals known in pre‑clinical work to modulate immune activity and HPA‑axis signaling. The trial thus offers one of the first human data points that such compounds can translate into measurable endocrine changes.

Why This Matters – And Why We Should Remain Cautious

The headline is tempting: a natural supplement that lowers anxiety, lifts mood, eases fatigue and improves sleep without side effects. For a public increasingly skeptical of pharmaceuticals yet eager for wellness solutions, that narrative resonates.

Yet the trial also underscores the challenges of moving from “promising” to “proven.”

1. Sample size: Fifty participants is modest. Even with randomization, small groups can be vulnerable to baseline imbalances that inflate apparent effects.
2. Population details: The abstract does not specify age distribution, gender balance or baseline severity of stress. Without knowing who the participants were, we cannot gauge generalizability to older adults or individuals with clinical anxiety disorders.
3. Effect magnitude: Statistical significance does not guarantee clinical relevance. A drop in PSQI score of 1–2 points can be statistically detectable but may not translate into a perceptible night‑time improvement for most sleepers.
4. Duration and follow‑up: The longest observation point is 12 weeks. Whether benefits persist after cessation, or whether longer use leads to tolerance, remains unknown.
5. Placebo composition: The abstract does not describe the placebo’s constituents. If the placebo contained any active ingredients (e.g., vitamins), it could attenuate observed differences.
6. Multiple comparisons: The study examined dozens of outcomes (several questionnaires, five biomarkers). Without correction for multiple testing, some reported p‑values could be false positives.

In short, the trial provides an intriguing proof‑of‑concept that a mushroom blend can influence both subjective well‑being and stress‑related hormones. It does not, however, settle the question of whether Restake should replace existing anxiety or sleep interventions.

What It Does Not Prove

• Causality for clinical disorders. The participants were not diagnosed with major depressive disorder, generalized anxiety disorder or insomnia. The findings cannot be extrapolated to therapeutic use in those conditions.
• Long‑term safety. The study lasted 12 weeks; rare adverse events that emerge after months of use would not be captured.
• Superiority over existing treatments. No head‑to‑head comparison with, for example, cognitive‑behavioral therapy, prescription anxiolytics or melatonin supplements was performed.
• Mechanistic specificity. While cortisol and ACTH fell, we cannot pinpoint which mushroom species or bioactive compounds drove the change, nor rule out indirect effects such as improved sleep leading to lower stress hormones.
• Effect in diverse populations. The sample size and lack of demographic breakdown preclude conclusions about efficacy across ages, ethnicities or comorbid health conditions.

Frequently Asked Questions

Q: What exactly is Restake?
A: Restake is a proprietary blend of several medicinal mushroom species marketed as an “adaptogenic” supplement. The precise composition is not disclosed in the study, but typical adaptogenic blends include reishi, lion’s mane, cordyceps and chaga.

Q: Can I take Restake instead of my prescribed anxiety medication?
A: No. The trial involved healthy volunteers with moderate stress, not patients with a diagnosed anxiety disorder. Always consult a healthcare professional before changing any medication regimen.

Q: How quickly did participants notice changes?
A: Outcomes were measured at 6‑week and 12‑week intervals. Significant improvements in anxiety, depression, fatigue and sleep quality were already evident at 6 weeks.

Q: Are there any side effects?
A: The authors report that Restake was “well tolerated” with no adverse effects observed during the 12‑week period. Larger and longer studies are needed to confirm safety.

Q: Does the supplement affect hormone levels in a way that could be harmful?
A: The measured reductions in cortisol, ACTH, norepinephrine and CRP are generally interpreted as a dampening of the stress response, not a pathological suppression. Hormone modulation can have complex downstream effects, and the clinical significance of these changes remains uncertain.

Sources

• Adaptogenic Effects of Mushroom Blend Supplementation on Stress, Fatigue, and Sleep: A Randomised, Double‑Blind, and Placebo‑Controlled Trial. Brain and Behavior (2026). DOI: https://doi.org/10.1002/brb3.71193

• (No additional related studies were supplied.)

Educational Disclaimer

This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.